Glp-1 weight loss denied as not medically necessary by Cigna?

Cigna's commercial coverage policy IP0206 targets liraglutide (Saxenda, generic), Wegovy, and Zepbound for chronic weight management and requires prior authorization. For adult initial therapy, the patient must have a BMI ≥ 30 kg/m² (obesity), or a BMI exceeding 30 or a comorbid condition, such as diabetes or hypertension, with a BMI over 27 ; recognized weight-related comorbidities include hypertension, Type 2 diabetes, dyslipidemia (high cholesterol), obstructive sleep apnea, or cardiovascular disease . Pediatric criteria require BMI ≥ 95th percentile for age and sex . Initial approval durations differ by product: approve for 4 months for Saxenda initial therapy , approve for 7 months of Wegovy initial therapy , and approve for 8 months of Zepbound initial therapy , with 1-year reauthorization contingent on continued therapy and demonstrated weight-loss response. For continuation, response to pharmacologic therapy should be assessed after 3 months on a therapeutic dose; if treatment has not resulted in ≥ 5% weight loss, longer-term efficacy will not likely be sufficient and a change is recommended; individuals with weight reduction ≥ 5% should continue with their current treatment . Additional MACE-reduction coverage exists for Wegovy in adults with established cardiovascular disease with overweight or obesity (e.g., prior MI, stroke, or symptomatic peripheral arterial disease), and Wegovy for MASH/NASH must be prescribed by or in consultation with a physician who specializes in the condition being treated ; Wegovy is not indicated in patients with cirrhotic (F4) MASH . Combined use with another GLP-1 or GLP-1/GIP agonist is not approved, and quantity limits restrict claims to one GLP-1 agonist at a time.

- For BMI/comorbidity denials: cite FDA labeling and AACE/Obesity Society guidelines supporting pharmacotherapy at BMI ≥ 30 or ≥ 27 with comorbidities; submit chart documentation of measured BMI and ICD-10-coded comorbidity (HTN, T2DM E11, OSA G47.33, dyslipidemia E78). - For lifestyle-modification denials: provide documented participation in a structured reduced-calorie diet, physical activity, and behavioral counseling, consistent with the policy's own framework that treatment is to address complications and diseases, not solely to reduce BMI, and the choice of pharmacotherapy is based on obesity-related comorbidities ; reference the STEP and SURMOUNT trial protocols which paired drug therapy with lifestyle intervention. - For inadequate-response denials at reauthorization: provide weighed clinic measurements showing ≥ 5% loss; note the policy itself acknowledges patients who achieve ≥ 15% weight loss (the average observed with Wegovy and Zepbound) achieve a response that predictably prevents or improves a wide range of complications — supported by STEP 1 (Wilding NEJM 2021) and SURMOUNT-1 (Jastreboff NEJM 2022). - For cardiovascular indication denials on Wegovy: cite the SELECT trial (Lincoff NEJM 2023) showing 20% MACE reduction; per policy, established cardiovascular disease with overweight or obesity is approvable with documentation of prior MI, stroke, or symptomatic PAD. - For OSA-related denials on Zepbound: cite SURMOUNT-OSA results referenced in the policy itself — in both trials, Zepbound was superior to placebo for the primary endpoint; in Trial 1, the change in AHI at Week 52 with Zepbound was superior to placebo (-25.3 events/hour vs. -5.3 events/hour) ; align with ATS 2018 OSA weight-management guideline recommending anti-obesity pharmacotherapy in BMI ≥ 27 patients. - For MASH/NASH denials on Wegovy: provide specialist (hepatology/GI) attestation and documentation of stage F2 or F3 fibrosis confirmed by liver biopsy within 3 years, vibration-controlled elastography (VCTE), or MRE ; cite ESSENCE trial results. - For "not medically necessary" denials: reference ADA Standards of Care 2024 and AACE 2023 endorsing GLP-1 RAs and GLP-1/GIP agonists for chronic weight management with cardiometabolic comorbidities, and the AHA 2021 Scientific Statement on obesity and CVD risk.

## Why Cigna Denies GLP-1 Weight-Loss Treatment on Medical-Necessity Grounds

Cigna's medical-necessity denials for GLP-1 agonists prescribed for weight management typically occur because the submitted documentation did not satisfy one or more of the criteria in Cigna's coverage policy. Common gaps include insufficient documentation of the patient's diagnosis (obesity or a related weight-linked comorbidity), absence of records showing prior behavioral or pharmacological weight-loss attempts, or a prescriber note that does not explicitly address the clinical severity of the patient's condition. Because Cigna's criteria for this drug class are specific and multi-part, a general chart note often fails to check every required box.

## Why This Denial Is Appealable

GLP-1 agonists for weight management have FDA approval and are endorsed by major obesity medicine and endocrinology professional societies as appropriate pharmacotherapy for patients who meet the clinical profile described in the prescribing information. If your prescriber made an individualized clinical determination that you meet those criteria, a well-documented appeal can demonstrate that the denial resulted from missing or inadequately presented records — not from a genuine clinical disqualification.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal within the deadline on the denial notice. Request the specific criterion or criteria Cigna found unmet — the plan is required to tell you.
• Peer-to-peer review: Ask your prescriber to request a clinical peer-to-peer call with Cigna's medical director. Many medical-necessity denials for this drug class are resolved at this stage when the clinical record is presented directly.
• External review (ACA §2719): After internal exhaustion, request independent external review. External reviewers evaluate the full clinical record without deference to Cigna's internal coverage policy. Standard decisions arrive within 45 days; expedited within 72 hours for urgent cases.

## Documentation to Gather

• Diagnosis confirmation: Documentation of obesity or the specific weight-related comorbidity (e.g., type 2 diabetes, cardiovascular disease, hypertension, sleep apnea) by the treating physician, with dates.
• Prior weight-loss treatment history: Records of previous attempts at behavioral intervention (dietary counseling, structured programs) and/or prior pharmacotherapy — with dates, duration, and documented outcomes. This is the category most commonly missing from initial submissions.
• Clinical severity: Chart notes addressing the patient's current clinical status, symptom burden, and the impact of excess weight on the documented comorbidities.
• Prescriber medical-necessity letter: A structured letter that walks through each of Cigna's stated coverage criteria one by one, cites the FDA-approved prescribing information and the applicable professional society guideline, and maps each criterion to a specific dated chart entry.

## Criteria-Mapping Structure

Download Cigna's current coverage policy for GLP-1 agonists in weight management from Cigna's medical policy library (search "obesity" or the drug's brand name on Cigna's provider site, or request it from member services). Then:

| Coverage Criterion (from Cigna policy) | Satisfying Document and Chart Reference | |---|---| | Diagnosis of obesity or qualifying comorbidity | [Physician diagnosis note, date] | | Prior behavioral or pharmacological treatment | [Program records, prescription history, dates and outcomes] | | Prescriber specialty or attestation | [Credentials and letter] | | [Any additional criteria listed] | [Corresponding chart entry or test result] |

A criterion-by-criterion response — rather than a general narrative — is the most effective format for a Cigna medical-necessity appeal.